GlassScriptPhysician profile
Stephen Bradford Fortson
NPI 1073819058
$11,799.90
in general payments reported to CMS, 2019-2025
56 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $1,324 · 2021: $1,984 · 2022: $2,402 · 2023: $1,834 · 2024: $1,309 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,388 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,387.80 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,768.93 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,042.82 | 2021-2025 | |
| Amgen INC. | $676.15 | 2019-2024 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $592.66 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $584.84 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $545.49 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $542.51 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $530.06 | 2019-2022 | |
| Glaxosmithkline, LLC. | $436.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $383.53 | 2019-2022 | |
| Corium, LLC | $337.67 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $309.43 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.56 | 2019-2025 | Xifaxan, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.87 | 2020-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $209.73 | 2021-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Fortson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.